This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Makower, D. Articles by Wadler, S. Search for Related Content PubMed PubMed Citation Articles by Makower, D. Articles by Wadler, S.

Phase II Clinical Trial of Intralesional Administration of the Oncolytic Adenovirus ONYX-015 in Patients with Hepatobiliary Tumors with Correlative p53 Studies¹

Division of Hematology/Oncology, Department of Medicine [S. W., M. E. L.], Weill Medical College of Cornell University, New York, New York 10021; Departments of Surgery [H. K.], Radiology [A. R.], Medicine [D. M., H. H.], and Pathology [M. E.], Albert Einstein College of Medicine and the Albert Einstein Cancer Center, Bronx, New York 10463; and Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, NIH, Bethesda, Maryland [J. Z.]

Purpose: ONYX-015 is a genetically modified adenovirus with a deletion of the E1B early gene and is therefore designed to replicate preferentially in p53-mutated cells. A Phase II trial of intralesional ONYX-015 was conducted in patients with hepatobiliary tumors to determine the safety and efficacy of such a treatment.

Experimental Design: All patients had biopsy-proven, measurable tumors of the liver, gall bladder, or bile ducts that were beyond the scope of surgical resection. Patients received intralesional injections of ONYX-015 at either 6 x 10⁹ or 1 x 10¹⁰ plaque-forming units/lesion up to a total dose of 3 x 10¹⁰ plaque-forming units, and i.p. injections were allowed in patients with malignant ascites. The status of p53 was assessed by immunohistochemistry or Affymetrix GeneChip microarray analysis. Studies were conducted for viral shedding and for the presence of antiadenoviral antibodies before and after the injection of ONYX-015. Patients were assessed for response and toxicity.

Results: Twenty patients were enrolled, and 19 patients were eligible. Half of the patients had primary bile duct carcinomas. Serious toxicities (> grade 2) were uncommon and included hepatic toxicity (three patients), anemia (one patient), infection (one patient), and cardiac toxicity (one patient, atrial fibrillation). Sixteen patients were evaluable for response. Among these evaluable patients, 1 of 16 (6.3%) had a partial response, 1 of 16 (6.3%) had prolonged disease stabilization (49 weeks), and 8 of 16 (50%) had a >50% reduction in tumor markers. Of the 19 eligible patients, 18 (94.7%) had specimens available for p53 analysis. Fifteen of these 18 patients (83.3%) had evidence of p53 mutation by one or both methods, although the methods correlated poorly. Viral shedding was confined to bile (two of two patients) and ascites (four of four patients). Pretreatment adenoviral antibodies were present in 14 of 14 patients and increased by 33.2% after ONYX-015 treatment.

Conclusions: Intralesional treatment with ONYX-015 in patients with hepatobiliary tumors is safe and well tolerated, and some patients had evidence of an anticancer effect. The high incidence of p53 mutations in these tumors makes this a logical population in which to test this therapy but precludes definitive evaluation about the necessity of a p53 mutation for ONYX-015 clinical activity.

This article has been cited by other articles:

				C. Su, M. Na, J. Chen, X. Wang, Y. Liu, W. Wang, Q. Zhang, L. Li, J. Long, X. Liu, et al. Gene-Viral Cancer Therapy Using Dual-Regulated Oncolytic Adenovirus with Antiangiogenesis Gene for Increased Efficacy Mol. Cancer Res., April 1, 2008; 6(4): 568 - 575. [Abstract] [Full Text] [PDF]

				N. Li, J. Zhou, D. Weng, C. Zhang, L. Li, B. Wang, Y. Song, Q. He, D. Lin, D. Chen, et al. Adjuvant Adenovirus-Mediated Delivery of Herpes Simplex Virus Thymidine Kinase Administration Improves Outcome of Liver Transplantation in Patients with Advanced Hepatocellular Carcinoma Clin. Cancer Res., October 1, 2007; 13(19): 5847 - 5854. [Abstract] [Full Text] [PDF]

				M. Wakayama, M. Abei, R. Kawashima, E. Seo, K. Fukuda, H. Ugai, T. Murata, N. Tanaka, I. Hyodo, H. Hamada, et al. E1A, E1B Double-Restricted Adenovirus with RGD-Fiber Modification Exhibits Enhanced Oncolysis for CAR-Deficient Biliary Cancers Clin. Cancer Res., May 15, 2007; 13(10): 3043 - 3050. [Abstract] [Full Text] [PDF]

				M E Guicciardi and G J Gores Apoptosis: a mechanism of acute and chronic liver injury Gut, July 1, 2005; 54(7): 1024 - 1033. [Full Text] [PDF]

				S. Wadler, H. Kaufman, M. Horwitz, S. Morley, D. Kirn, R. Brown, S. Kaye, and D. Soutar The dl1520 Virus Is Found Preferentially in Tumor Tissue after Direct Intratumoral Injection in Oral Carcinoma Clin. Cancer Res., April 1, 2005; 11(7): 2781 - 2782. [Full Text] [PDF]

				V. V. Ternovoi, L. P. Le, N. Belousova, B. F. Smith, G. P. Siegal, and D. T. Curiel Productive Replication of Human Adenovirus Type 5 in Canine Cells J. Virol., January 15, 2005; 79(2): 1308 - 1311. [Abstract] [Full Text] [PDF]

				E. A. Sausville Genes in the Service of Therapeutic Index: Progress for Virus-Directed Enzyme Prodrug Therapy J. Clin. Oncol., May 1, 2004; 22(9): 1535 - 1537. [Full Text] [PDF]

				I. Ganly and B. Singh Topical ONYX-015 in the Treatment of Premalignant Oral Dysplasia: Another Role for the Cold Virus? J. Clin. Oncol., December 15, 2003; 21(24): 4476 - 4478. [Full Text] [PDF]